Literature DB >> 3680221

Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist.

A Green1.   

Abstract

Adenosine, via interaction with A1 adenosine receptors, increases insulin sensitivity and inhibits lipolysis in adipocytes. To investigate regulation of this system, adipocytes were incubated for up to 72 h with the nonmetabolizable adenosine receptor agonist, N6-phenylisopropyl adenosine (PIA). Adenosine receptors were measured by the binding of 125I-hydroxyphenylisopropyl adenosine to membranes. PIA down-regulated adenosine receptors, decreasing the number of binding sites with no change in affinity. Adipocytes were incubated for 48 h without or with 100 nM PIA to down-regulate the A1 receptors by approximately 60%. The cells were washed, and lipolysis and glucose transport were assessed. The ability of PIA to inhibit lipolysis was markedly attenuated in the down-regulated cells. Furthermore, the EC50 of insulin was increased approximately 3-fold in the PIA-treated cells. 125I-Insulin binding to the PIA-treated cells was unchanged, demonstrating that the decreased insulin sensitivity is not due to decreased insulin receptor binding. Pertussis toxin catalyzed ADP-ribosylation of a 41-kDa protein thought to be the alpha-subunit of Gi. This 41-kDa protein was decreased in membranes from cells treated with PIA, with a maximal 50% loss. This suggests that Gi is down-regulated and that loss of both the A1 adenosine receptor and Gi are involved in the metabolic changes observed after PIA treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680221

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Tonic activity of the rat adipocyte A1-adenosine receptor.

Authors:  Hui-Xiu Liang; Luiz Belardinelli; Mark J Ozeck; John C Shryock
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Quantitative autoradiography of adenosine receptors in brains of chronic naltrexone-treated mice.

Authors:  Alexis Bailey; Rachel M Hawkins; Susanna M O Hourani; Ian Kitchen
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

3.  Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells.

Authors:  V Ramkumar; M E Olah; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1991-11       Impact factor: 4.436

4.  Role of guanine nucleotide regulatory proteins in insulin stimulation of glucose transport in rat adipocytes. Influence of bacterial toxins.

Authors:  T P Ciaraldi; A Maisel
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

5.  Evidence for altered expression of the GTP-dependent regulatory proteins, Gs and Gi, in adipocytes from aged rats.

Authors:  A Green; J L Johnson
Journal:  Biochem J       Date:  1989-03-01       Impact factor: 3.857

6.  Thyrotropin regulates adenosine A(1) receptor expression in rat thyroid FRTL-5 cells.

Authors:  M Vainio; B B Fredholm; K Törnquist
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

7.  Beta adrenoreceptor subtype cross regulation in the human heart.

Authors:  J A Hall; A Ferro; J E Dickerson; M J Brown
Journal:  Br Heart J       Date:  1993-04

8.  Adenosine A1 receptors mediate chronic ethanol-induced increases in receptor-stimulated cyclic AMP in cultured hepatocytes.

Authors:  L E Nagy; S E DeSilva
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

9.  A1 adenosine receptors and muscarinic cholinoceptors in myocardial ischemia.

Authors:  M Ungerer; M Stocker; G Richardt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-06       Impact factor: 3.000

10.  Loss of myocardial protection from ischemic preconditioning following chronic exposure to R(-)-N6-(2-phenylisopropyl)adenosine is related to defect at the adenosine A1 receptor.

Authors:  M W Hashimi; J D Thornton; J M Downey; M V Cohen
Journal:  Mol Cell Biochem       Date:  1998-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.